ClinicalTrials.gg
CompletedNCT07047027Updated Jul 2, 2025

Comparative Analysis of Root Canal Microbiota in Diabetic and Systemically Healthy Patients

An observational study in Root Canal Infection, sponsored by Bulent Ecevit University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-02.

Sponsored by Bulent Ecevit University · Observational

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
39
Ages
18 Years and older
Sex
All
01

Study summary

The objective of this study was to assess the influence of Diabetes Mellitus on the microbial flora involved in root canal infections through a comparative analysis with that of systemically healthy patients.

Read the detailed description

A total of 39 participants aged 18 to 65 years were enrolled in the study, including 21 patients with Diabetes Mellitus and 18 systemically healthy individuals (controls). In the diabetic group, 12 teeth were diagnosed with persistent endodontic infections (SEI) and 9 with primary endodontic infections (PEI). In the healthy group, 12 teeth presented with SEI and 6 with PEI. Root canal samples were obtained using sterile paper points, transferred into Eppendorf tubes containing phosphate-buffered saline (PBS), and stored at -80 °C until analysis. The V3-V4 hypervariable regions of 16S rRNA from both sample types were amplified and sequenced using the Illumina MiSeq platform. Amplicon sequence variants (ASVs), generated via the DADA2 pipeline, were analyzed in the QIIME2 environment and taxonomically assigned using the SILVA database. Microbial richness and diversity were assessed using alpha diversity indices (Chao1, Shannon, Simpson, Faith's PD, Fisher alpha) and beta diversity metrics (Bray-Curtis, Jaccard, Unweighted UniFrac, and Weighted UniFrac). Alpha and beta diversity metrics were compared using the Kruskal-Wallis test and pairwise permutational multivariate analysis of variance (PERMANOVA), respectively, via the phyloseq package in R (version 4.1). Differentially abundant taxa were identified using Linear Discriminant Analysis Effect Size (LEfSe).

02

Conditions studied

  • Root Canal Infection
03

In context

Lead sponsor

Bulent Ecevit University is the lead sponsor of 47 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients who were attended to the faculty of dentistry

Eligibility criteria

Inclusion Criteria:The inclusion criteria for patient selection were as follows: patients in the diabetic group were required to have a diagnosis of type 2 Diabetes Mellitus with no other systemic diseases; patients in the control group had to be systemically healthy with no history of any systemic illness. All participants must not have used antibiotics within the past three months, must not be pregnant, and must have teeth with intact coronal restorations that prevent direct pulp exposure to the oral environment. Only asymptomatic teeth diagnosed with chronic apical periodontitis and a Periapical Index (PAI) score of 3 or higher were included -

Exclusion Criteria:The exclusion criteria were: teeth with extensive coronal destruction that would prevent rubber dam isolation, presence of pain, swelling, or sinus tract, presence of root or crown fractures, and periodontal pockets deeper than 3 mm.

-

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
39 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Microbial analysis

    Root canal microbial flora

    Time frame: 8 weeks

07

Study locations

1 site
  • Faculty of Dentistry of Bulent Ecevit University, Zonguldak,
    Zonguldak, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2024 to primary completion in Feb 2025, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2025
First posted
Jul 2, 2025
StartActual
Sep 2, 2024
Primary completionActual
Feb 21, 2025
CompletionActual
Mar 13, 2025
Last update
Jul 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07047027
Lead sponsor
Bulent Ecevit University
Responsible party
Sevinç Aktemur Türker (Professor, Bulent Ecevit University) — Principal investigator
First posted
Jul 2, 2025
Start date
Sep 2, 2024
Primary completion
Feb 21, 2025
Completion
Mar 13, 2025
Last update
Jul 2, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion